185 related articles for article (PubMed ID: 12836015)
21. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
23. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
[TBL] [Abstract][Full Text] [Related]
24. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Seliger B; Hohne A; Knuth A; Bernhard H; Meyer T; Tampe R; Momburg F; Huber C
Cancer Res; 1996 Apr; 56(8):1756-60. PubMed ID: 8620489
[TBL] [Abstract][Full Text] [Related]
26. Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha.
Nagy N; Vánky F; Klein E
Immunol Lett; 1998 Dec; 64(2-3):153-60. PubMed ID: 9870667
[TBL] [Abstract][Full Text] [Related]
27. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients.
Sommerfeldt N; Schütz F; Sohn C; Förster J; Schirrmacher V; Beckhove P
Cancer Res; 2006 Aug; 66(16):8258-65. PubMed ID: 16912206
[TBL] [Abstract][Full Text] [Related]
28. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
Vitale M; Rezzani R; Rodella L; Zauli G; Grigolato P; Cadei M; Hicklin DJ; Ferrone S
Cancer Res; 1998 Feb; 58(4):737-42. PubMed ID: 9485029
[TBL] [Abstract][Full Text] [Related]
29. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
30. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells.
Ramakrishna V; Negri DR; Brusic V; Fontanelli R; Canevari S; Bolis G; Castelli C; Parmiani G
Int J Cancer; 1997 Sep; 73(1):143-50. PubMed ID: 9334822
[TBL] [Abstract][Full Text] [Related]
31. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
Correale P; Aquino A; Giuliani A; Pellegrini M; Micheli L; Cusi MG; Nencini C; Petrioli R; Prete SP; De Vecchis L; Turriziani M; Giorgi G; Bonmassar E; Francini G
Int J Cancer; 2003 Apr; 104(4):437-45. PubMed ID: 12584740
[TBL] [Abstract][Full Text] [Related]
32. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes.
Riker AI; Kammula US; Panelli MC; Wang E; Ohnmacht GA; Steinberg SM; Rosenberg SA; Marincola FM
Int J Cancer; 2000 Jun; 86(6):818-26. PubMed ID: 10842196
[TBL] [Abstract][Full Text] [Related]
33. Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines.
Kaczmarek M; Frydrychowicz M; Rubis B; Mizera-Nyczak E; Nieruchalska E; Sikora J; Kaczmarek E
Folia Histochem Cytobiol; 2007; 45(3):205-14. PubMed ID: 17951169
[TBL] [Abstract][Full Text] [Related]
34. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
35. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
36. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
37. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
[TBL] [Abstract][Full Text] [Related]
38. Is tumor expression of the major histocompatibility complex antigen required for T cell immune surveillance?
Liu Y; Zheng P
Arch Immunol Ther Exp (Warsz); 2001; 49 Suppl 2():S61-4. PubMed ID: 11665749
[TBL] [Abstract][Full Text] [Related]
39. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
[TBL] [Abstract][Full Text] [Related]
40. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.
Wang F; Li X; Annis B; Faustman DL
Hum Gene Ther; 1995 Aug; 6(8):1005-17. PubMed ID: 7578413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
